Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 21:15:1456559.
doi: 10.3389/fneur.2024.1456559. eCollection 2024.

Efficacy and safety of different doses of vamorolone in boys with Duchenne muscular dystrophy: a systematic review and network meta-analysis

Qin Wang  1 , Yaqing Zeng  1 , Linna Jiao  1 , Jianli He  1 , Baoyi Li  1 , Yihua Guo  1 , Zhibin Song  1
Affiliations

Efficacy and safety of different doses of vamorolone in boys with Duchenne muscular dystrophy: a systematic review and network meta-analysis

Qin Wang et al. Front Neurol. .

Abstract

Background and objectives: Several recent clinical studies have indicated that vamorolone is comparable in effectiveness to glucocorticosteroids for treating Duchenne muscular dystrophy (DMD). However, there is a lack of extensive data regarding the efficacy and safety of various doses of vamorolone. We conducted a study to evaluate the efficacy of different doses of vamorolone in boys with DMD, and compare the safety of vamorolone vs. glucocorticosteroids, prednisone or deflazacort in boys with DMD.

Methods: We performed systematic searches of the PubMed, Embase, and Cochrane Library databases for vamorolone, glucocorticosteroids, prednisone or deflazacort in boys with DMD. We assessed statistical heterogeneity across trials based on the Newcastle Ottawa scale (NOS) tool test and I2 values, and mean differences were pooled using the random-effects model. We used traditional meta-analysis to evaluate efficacy and safety of vamorolone 6.0 mg/kg/d vs. vamorolone 2.0 mg/kg/d and vamorolone vs. prednisone. A network meta-analysis was applied to estimated the safety of vamorolone in comparison to glucocorticosteroids, prednisone and deflazacort. Our meta-analysis were performed using Revman 5.4 software, and our network meta-analysis were performed using Stata/MP 18.0.

Results: In the meta-analysis, a total of 193 patients were analyzed across four clinical trials (97 patients receiving vamorolone 2 mg/kg per day; 96 patients receiving vamorolone 2 mg/kg per day). We observed that there were statistically significant differences in boys with DMD between vamorolone 6.0 mg/kg/d and vamorolone 2.0 mg/kg/d in TTSTANDV (MD = 0.03, 95%CI = 0.00-0.06, p = 0.04), TTRWV (MD = 0.13, 95%CI = 0.08-0.19, p < 0.01), 6MWT (MD = 24.54, 95%CI = 4.46-44.82, p = 0.02), TTCLIMBV (MD = 0.04, 95%CI = 0.01-0.06, p = 0.009), no significant difference in BMI z score (MD = 0.09, 95%CI = -0.03-0.20, p = 0.13). Indirect comparisons derived from network meta-analysis did not show significant differences among vamorolone, glucocorticosteroids, prednisone and deflazacort in BMI z score.

Conclusion: Our findings implied that boys with DMD who took vamorolone 6 mg/kg daily instead of 2 mg/kg daily may be safer and have superior motor function. However, more large sample randomized controlled trials are needed to confirm our results.

Systematic review registration: This systematic review and meta-analysis has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO (registration number: CRD42024562916).

Keywords: Duchenne muscular dystroph; deflazacort; glucocorticosteroids; prednisone; vamorolone.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow diagram describing the systematic literature search and study selection.
Figure 2
Figure 2
Forest plot of TTSTAND velocity outcome data for vamorolone 6.0 mg/kg/d vs. vamorolone 2.0 mg/kg/d.
Figure 3
Figure 3
Forest plot of TTRW velocity outcome data for vamorolone 6.0 mg/kg/d vs. vamorolone 2.0 mg/kg/d.
Figure 4
Figure 4
Forest plot of 6MWT velocity outcome data for vamorolone 6.0 mg/kg/d vs. vamorolone 2.0 mg/kg/d.
Figure 5
Figure 5
Forest plot of TTCLIMB velocity outcome data for vamorolone 6.0 mg/kg/d vs. vamorolone 2.0 mg/kg/d.
Figure 6
Figure 6
Forest plot of BMI z score outcome data for vamorolone 6.0 mg/kg/d vs. vamorolone 2.0 mg/kg/d.
Figure 7
Figure 7
Forest plot of BMI z score outcome data for vamorolone vs. prednisone.
Figure 8
Figure 8
Forest plot of mean height percentile for age outcome data for vamorolone vs. prednisone.
Figure 9
Figure 9
Network meta-analysis for vamorolone vs. glucocorticosteroid, prednisone and deflazacort of BMI z score.
See this image and copyright information in PMC

Similar articles

  • Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, Kerchner L, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, Gordish-Dressman H, Hagerty L, Dang UJ, Damsker JM, Schwartz BD, Mengle-Gaw LJ, McDonald CM; CINRG VBP15 and DNHS Investigators. Smith EC, et al. PLoS Med. 2020 Sep 21;17(9):e1003222. doi: 10.1371/journal.pmed.1003222. eCollection 2020 Sep. PLoS Med. 2020. PMID: 32956407 Free PMC article. Clinical Trial.
  • Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, Mah JK, Deconinck N, Goemans N, Haberlova J, Straub V, Mengle-Gaw LJ, Schwartz BD, Harper AD, Shieh PB, De Waele L, Castro D, Yang ML, Ryan MM, McDonald CM, Tulinius M, Webster R, McMillan HJ, Kuntz NL, Rao VK, Baranello G, Spinty S, Childs AM, Sbrocchi AM, Selby KA, Monduy M, Nevo Y, Vilchez-Padilla JJ, Nascimento-Osorio A, Niks EH, de Groot IJM, Katsalouli M, James MK, van den Anker J, Damsker JM, Ahmet A, Ward LM, Jaros M, Shale P, Dang UJ, Hoffman EP. Guglieri M, et al. JAMA Neurol. 2022 Oct 1;79(10):1005-1014. doi: 10.1001/jamaneurol.2022.2480. JAMA Neurol. 2022. PMID: 36036925 Free PMC article. Clinical Trial.
  • Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
    Dang UJ, Damsker JM, Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, Mah JK, Deconinck N, Goemans NM, Haberlová J, Straub V, Mengle-Gaw L, Schwartz BD, Harper A, Shieh PB, De Waele L, Castro D, Yang ML, Ryan MM, McDonald CM, Tulinius M, Webster RI, Mcmillan HJ, Kuntz N, Rao VK, Baranello G, Spinty S, Childs AM, Sbrocchi AM, Selby KA, Monduy M, Nevo Y, Vilchez JJ, Nascimento-Osorio A, Niks EH, De Groot IJM, Katsalouli M, Van Den Anker JN, Ward LM, Leinonen M, D'Alessandro AL, Hoffman EP. Dang UJ, et al. Neurology. 2024 Mar 12;102(5):e208112. doi: 10.1212/WNL.0000000000208112. Epub 2024 Feb 9. Neurology. 2024. PMID: 38335499 Free PMC article. Clinical Trial.
  • Meta-analysis of the efficacy and safety of vamorolone in Duchenne muscular dystrophy.
    Ibrahim MS, Abdelwahab OA, Elawfi B, Ali FY, Amro S, Mohammed SF, Shaheen N, Negida A, Arndt M, Hijazi MM, Schaefer J, Siepmann T. Ibrahim MS, et al. Neurol Sci. 2025 May;46(5):2249-2262. doi: 10.1007/s10072-024-07939-1. Epub 2024 Dec 24. Neurol Sci. 2025. PMID: 39715964 Free PMC article.
  • Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis.
    Elhalag RH, Motawea KR, Talat NE, Rouzan SS, Shah J. Elhalag RH, et al. Front Neurol. 2023 Feb 1;14:1107474. doi: 10.3389/fneur.2023.1107474. eCollection 2023. Front Neurol. 2023. PMID: 36816559 Free PMC article.
See all similar articles

References

    1. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. (2021) 7:13. doi: 10.1038/s41572-021-00248-3, PMID: - DOI - PMC - PubMed
    1. Happi Mbakam C, Lamothe G, Tremblay JP. Therapeutic strategies for dystrophin replacement in Duchenne muscular dystrophy. Front Med (Lausanne). (2022) 9:859930. doi: 10.3389/fmed.2022.859930, PMID: - DOI - PMC - PubMed
    1. Deng J, Zhang J, Shi K, Liu Z. Drug development progress in duchenne muscular dystrophy. Front Pharmacol. (2022) 13:950651. doi: 10.3389/fphar.2022.950651 - DOI - PMC - PubMed
    1. Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. (2019) 15:373–86. doi: 10.1038/s41582-019-0203-3 - DOI - PubMed
    1. Berling E, Nicolle R, Laforêt P, Ronzitti G. Gene therapy review: Duchenne muscular dystrophy case study. Rev Neurol (Paris). (2023) 179:90–105. doi: 10.1016/j.neurol.2022.11.005, PMID: - DOI - PubMed

Publication types

LinkOut - more resources